Abstract
The mucosal immune system plays a fundamental role in maintaining microbial balance. Microbial imbalance in the female genital tract increases the risk for adverse health outcomes in women and may increase susceptibility to genital tract infections. Among different relevant immune subsets, myeloid-derived suppressor cells (MDSCs) remain understudied in the context of female genital tract conditions. Here we show that frequency of polymorphonuclear (PMN-) MDSCs increased in the cervical mucosa of women with Chlamydia trachomatis, bacterial vaginosis, or with a coinfection, but not in women with human papillomavirus. Mucosal PMN-MDSC frequencies correlated with mucosal IL-1β in C. trachomatis patients and ex vivo exposure of cervical tissue to C. trachomatis elevated both PMN-MDSC frequencies and IL-1β secretion. Likewise, exposure of cervical tissue to cervicovaginal lavage fluid from C. trachomatis and bacterial vaginosis patients also enhanced PMN-MDSC frequencies. Lastly, cervical MDSCs expressed suppressive mediators and functionally suppressed cytotoxic T-cell responses. Our study identifies IL-1β-stimulated PMN-MDSCs as an immune suppressive mediator in female genital tract infections, potentially contributing to susceptibility to acquiring secondary infections at this site.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by: Fundació La Marató TV3 (FMTV3) grant 201814-10 (MG) Fundació La Marató TV3 (FMTV3) grant 202112-30 (MG) Spanish Health Institute Carlos III (ISCIII) co-funded by ERDF/ESF, "A way to make Europe"/"Investing in your future" grant PI20/00160 (MG) Gilead fellowship grant GLD18/00008 (MG) Spanish Health Institute Carlos III, Miguel Servet program grant CP17/00179 (MJB) Vall d'Hebron Institut de Recerca (VHIR) PhD Fellowship (NM)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Signed informed consent was obtained from all participants included in this study. This study was performed in accordance with the Declaration of Helsinki. Ethical approval was given by the corresponding Institutional Review Board (PR(AG)117/2018) of the Vall d'Hebron University Hospital (HUVH), Barcelona, Spain.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors have declared that no conflict of interest exists.
Updates throughout all sections of the manuscript, including, figures 1, 2, 4, 5, and 6.
